PEG-MGF vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | PEG-MGF | Retatrutide |
|---|---|---|
| Mechanism | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |